Evolus, Inc. (LON:0K16)

Market Cap	330.19M -26.0%
Revenue (ttm)	228.55M +9.6%
Net Income	-32.88M
EPS	-0.51
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52
Open	14.31
Previous Close	14.16
Day's Range	14.31 - 14.58
52-Week Range	9.31 - 17.81
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 31, 2026

About Evolus

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newpo...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 350
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K16

Financial Performance

In 2025, Evolus's revenue was $297.18 million, an increase of 11.61% compared to the previous year's $266.27 million. Losses were -$51.64 million, 2.42% more than in 2024.

Financial numbers in USD